Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Leerink Partners Upgrades Agios Pharmaceuticals to Outperform, Lowers Price Target to $34

Author: Benzinga Newsdesk | November 20, 2025 07:50am
Leerink Partners analyst Andrew Berens upgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Market Perform to Outperform and lowers the price target from $40 to $34.

Posted In: AGIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist